- Home
- Profiles
Deepu Madduri, MD
- About Me
- Clinical Focus
- Publications
- Industry Relationships
About Me
Language
Position
About Me
Language
Position
Clinical Focus
Publications
Selected Publications
- Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesus G. Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu min Yeh, Xiaoying Xu, Lida Pacaud, Muhammad Akram, Sundar Jagannath. Clinical Lymphoma, Myeloma and Leukemia
- Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Thomas G. Martin, Deepu Madduri, Lida Pacaud, Saad Z. Usmani. Future Oncology
- Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Yi Lin, Noopur S. Raje, Jesús G. Berdeja, David S. Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V. Maus, Monica Massaro, Fabio Petrocca, Ashish Yeri, Olivia Finney, Andrea Caia, Zhihong Yang, Nathan Martin, Timothy B. Campbell, Julie Rytlewski, Jaymes Fuller, Kristen Hege, Nikhil C. Munshi, James N. Kochenderfer. Nature Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Madduri has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.